GW Pharmaceuticals is a biopharmaceutical company that develops and markets cannabinoid prescription medicines using botanical extracts derived from the cannabis plant. It offers Epidiolex, oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and provides Sativex, a spray for the treatment of spasticity due to multiple sclerosis.